Holen Sie sich die Stockscreener-App
0.8596
1.39%
0.0118
Vorhandelsmarkt:
.86
0.0004
+0.05%
Schlusskurs vom Vortag:
$0.8478
Offen:
$0.8512
24-Stunden-Volumen:
1.06M
Relative Volume:
0.92
Marktkapitalisierung:
$91.86M
Einnahmen:
$33.03M
Nettoeinkommen (Verlust:
$-44.63M
KGV:
-2.0501
EPS:
-0.4193
Netto-Cashflow:
$-36.18M
1W Leistung:
+4.88%
1M Leistung:
+12.34%
6M Leistung:
-50.88%
1J Leistung:
-67.07%
1-Tages-Spanne:
$0.8079
$0.8662
1-Wochen-Bereich:
$0.8018
$0.8999
52-Wochen-Spanne:
$0.6434
$2.955
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
0.8596 | 90.60M | 33.03M | -44.63M | -36.18M | -0.4193 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
Form S-8Securities to be offered to employees in employee benefit plans - ADVFN
Wall Street Zen Downgrades MaxCyte (NASDAQ:MXCT) to Sell - MarketBeat
MaxCyte (MXCT) CFO receives 187,500 restricted stock units in equity grant - Stock Titan
MaxCyte (MXCT) price target decreased by 11.67% to 4.33 - MSN
Earnings Call Summary | MaxCyte(MXCT.US) Q4 2025 Earnings Conference - 富途牛牛
FOMO Trade: Is MaxCyte Inc stock risky to hold nowWeekly Profit Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Rally Mode: Can MaxCyte Inc sustain its profitability2026 Breakouts & Growth Focused Stock Reports - baoquankhu1.vn
Fed Watch: Will MaxCyte Inc benefit from rising consumer demand2026 Rallies & Weekly Sector Rotation Insights - baoquankhu1.vn
MaxCyte (MXCT) CFO awarded 375,000 employee stock options at $0.6762 - Stock Titan
MAXCYTE (MXCT) CFO Parmeet Ahuja named reporting insider in Form 3 - Stock Titan
Mirabella exit leaves MaxCyte (NASDAQ: MXCT) ownership at 0% after Jan 5, 2026 - Stock Titan
Activity Recap: Is MaxCyte Inc showing insider buying2026 WrapUp & Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Final Week: Is MaxCyte Inc being accumulated by smart money - baoquankhu1.vn
Aug Rallies: Is MaxCyte Inc a momentum stock2026 Intraday Action & Technical Pattern Alert System - baoquankhu1.vn
Pullback Watch: Is MaxCyte Inc forming a breakout patternWall Street Watch & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2025 earnings call transcript - MSN
Quarterly Earnings: Is MaxCyte Inc stock a value trap2026 Key Highlights & Growth Focused Entry Reports - baoquankhu1.vn
MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - MSN
MXCT PE Ratio & Valuation, Is MXCT Overvalued - Intellectia AI
MXCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Big Money Moves: Is MaxCyte Inc stock risky to hold now2026 News Drivers & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
MaxCyte (MXCT) CEO awarded 600,000 options and 300,000 RSUs - Stock Titan
New MaxCyte CFO gets 562,500-share inducement award under Nasdaq rule - Stock Titan
RSI Check: Is now the right time to enter MaxCyte IncTrade Entry Report & Long-Term Growth Portfolio Plans - baoquankhu1.vn
MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Parmeet Ahuja Net Worth (2026) - GuruFocus
Risk On: Will MaxCyte Inc outperform small cap indexes2026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn
MaxCyte sees Q4 core revenue between $6.6M and $6.7M - MSN
MaxCyte Appoints Parmeet Ahuja as New Chief Financial Officer to Drive Strategic Growth - Minichart
MaxCyte outlines $30M–$32M 2026 revenue target as ExPERT DTx launch and SPL milestones drive outlook - MSN
MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates - MSN
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside - The Globe and Mail
MaxCyte Appoints New Chief Financial Officer Ahuja - TipRanks
MaxCyte appoints Parmeet Ahuja as CFO, succeeding Douglas Swirsky - TradingView
New MaxCyte (NASDAQ: MXCT) CFO Parmeet Ahuja joins from Agilent - Stock Titan
Vanguard disaggregates holdings; reports 0% stake in MaxCyte (MXCT) - Stock Titan
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access - TipRanks
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
MaxCyte ExPERT Platform: Leading Non-Viral Cell Engineering Technology for Next-Generation Cell & Gene Therapy Development - Minichart
MaxCyte 2025 10‑K: Revenue $33.0M, EPS $(0.42) - TradingView
MaxCyte (NASDAQ: MXCT) details 2025 losses and $2B SPL upside - Stock Titan
MXCT: Craig-Hallum Maintains Buy Rating but Lowers Price Target - GuruFocus
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds By Investing.com - Investing.com Australia
Craig Hallum Issues Pessimistic Forecast for MaxCyte (NASDAQ:MXCT) Stock Price - MarketBeat
Stifel cuts MaxCyte stock price target on 2026 revenue guidance - Investing.com
Craig-Hallum cuts MaxCyte stock price target on FY25 headwinds - Investing.com
Stifel cuts MaxCyte stock price target on 2026 revenue guidance By Investing.com - Investing.com Australia
MaxCyte 2025 Financial Results Review - AlphaStreet
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):